


Claims

1. A compound of formula (I)(A):



wherein both dashed lines are a carbon-carbon double bond, or both are absent;

R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl;

each of R₅, R₆, R₇ and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;

W is R₉, O-R₉, NR₁₀, -(CO)(O)R₉, -N(R₁₀)SO₂-R₉, -O (CO)R₉, -(CO)NR₁₀, or -N(R₁₀)-CO-R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆ alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R₁₀ is H, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclic radical;

Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆ alkoxy;

Z is C₂₋₈ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅, SO₂R₁₅, SO₂N or CSR₁₅; or Z is NR₁₁R₁₂ where each of R₁₁ and R₁₂ is independently selected from H, C₁₋₆ alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and C₂₋₅ heterocyclic radical; and R₁₅ is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, or C₄₋₇ cycloalkenyl;

D2
Cat

5

10

15

20

25

30

provided that where R_c is $WNR_{11}R_{12}$, each of R_{11} and R_{12} being independently selected from C_{1-6} alkyl, then at least one of the following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is $-R_9-$, $-NR_{10}-$, $-(CO)(O)R_9-$, $-O(CO)R_9-$, $-(CO)NHR_9-$, or $-N(R_{10})(CO)R_9-$; and further provided that where each of R_a , R_b , R_d , and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent one carbon-carbon double bond or are absent; or R_7 or R_8 is alkyl, alkoxy, halo, or amino; and further provided that where each of R_a , R_b , R_d , and R_e is H, and W is a straight chain, unsubstituted propoxy, then YZ is not N-piperidyl or N-morpholinyl; and each of the above hydrocarbonyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, C_{2-5} heterocyclic radical, phenyl, and phenyl(C_{1-3} alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

2. A compound of claim 1, wherein Z comprises piperidyl, morpholinyl, benzyl amino, phenyl amino, substituted benzyl amino, piperazinyl, pyrrolidyl, or a C_{6-8} cycloalkylimino radical.
3. A compound of claim 1, wherein Z is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-4} alkyl, phenyl, and benzyl.
4. A compound of claim 1, wherein W is hydroxy-substituted C_{2-4} alkoxy, C_{2-4} alkoxy, C_{2-4} alkylamino, butenyl, or butynyl.

A2
cont

5

5. A compound of claim 1, wherein W comprises propoxy, ethoxy, propylamino, or ethylamino; and one of R_7 and R_8 is methyl.

6. A compound of claim 1, where R_7 is methyl.

7. A compound of claim 1 wherein at least one of R_a , R_b , R_d , and R_e is methyl.

10

A2
cont

8. A compound of claim 1, wherein each of R_5 , R_6 , R_7 and R_8 is independently H, methyl, ethyl, methoxy, ethoxy, fluoro, or chloro; or wherein one of R_a , R_b , R_c , R_d , and R_e is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, fluoro, or chloro; or both.

15

9. A compound of claim 1, wherein both dashed lines are present to form two carbon-carbon double bonds.

20

10. A compound of claim 1, wherein both dashed lines are absent.

11. A compound of claim 1, wherein R_a or R_e is methyl, fluoro, or methoxy.

12. A compound of claim 1, provided that where each of R_a , R_b , R_d , and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least two of the following are true: Z is cyclic; at least one of the dashed lines is absent; and R_7 or R_8 is methyl.

30

13. A compound of claim 1, provided that where R_c is $WNR_{11}R_{12}$, each of R_{11} and R_{12} being independently selected from C_{1-6} alkyl, then at least two of the following are true: R_b or R_d is methyl, methoxy, ethyl, ethoxy, or halo; or at least one of the dashed

lines is absent; or R_a or R_e is methyl, methoxy, ethyl, ethoxy, fluoro, or chloro; or W is R_9 , $-(CO)(O)R_9$, $-N(R_{10})SO_2-R_9$, $-O(CO)R_9$, $-(CO)NHR_9$, $-N(R_{10})-CO-R_9$, or NR_{10} .

5

14. A compound of claim 1, wherein

R_3 is H or methyl;

each of R_b and R_d is independently H, methyl, or methoxy;

each of R_7 and R_8 is independently H, methyl, fluoro, or chloro;

each of R_5 and R_6 is H;

each of R_a or R_e is independently H, methyl, fluoro, or chloro;

W is C_{2-4} alkoxy, C_4 alkylene, C_4 alkynylene, C_4 alkenylene, -

$N(R_{10})SO_2-(C_{1-5}$ alkyl), $-(CO)O-C_{2-3}$ alkyl, $-(CO)NH-(C_{1-3}$ alkyl), -

$NH(CO)(C_{1-3}$ alkyl), or $-NH(C_{1-6}$ alkyl); and

Z is pyrrolidyl, piperidyl, morpholinyl, piperazinyl, (piperidyl)-

piperidyl, or $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently

selected from H, C_{1-5} alkyl, phenyl, benzyl, C_{3-8} cycloalkyl, and C_{2-5}

heterocyclic radical, but at least one of R_{11} and R_{12} is not H; or

taken together, R_{11} and R_{12} with the N to which they are attached

form a C_{6-8} cycloalkylimino radical.

10

15

20

15. A compound of claim 2, selected from 2-[4-[3-

(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine;

(E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-

a]pyridine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-

pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methyl-imidazo[1,2-a]-pyridin-2-

yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-

Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-

(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-

a]pyridine; and N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-

2-yl)-phenyl]-propane-1,3-diamine.

25

30

16.

A compound of claim 2, selected from 2-(4-Piperidinopropoxy-2-

methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-

Cycloheptylamino propoxyphenyl)-7-methylimidazo[1,2-a]pyridine;
 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]
 pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]
 pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]
 pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]
 pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]
 pyridine; and 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]
 pyridine.

17. A compound of claim 2, selected from N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;
 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine;
 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine;
 and N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine.

18. A compound of claim 16, having the formula 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

19. A pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically-acceptable carrier.

20. A pharmaceutical composition of claim 19, wherein said compound has a formula wherein R_3 is H or methyl; each of R_b and R_d is independently H, methyl, or methoxy; each of R_7 and R_8 is independently H, methyl, fluoro, or chloro; each of R_5 and R_6 is H; each of R_a or R_e is independently H, methyl, fluoro, or chloro; W is C_{2-4} alkoxy, C_4 alkylene, C_4 alkynylene, C_4 alkenylene, $-(CO)O-C_{2-3}$ alkyl, $-N(R_{10})SO_2-R_9$, $-(CO)NH-(C_{1-3}$ alkyl), $-NH(CO)(C_{1-3}$ alkyl), or $NH(C_{1-6}$ alkyl); and Z is pyrrolidyl, piperidyl, morpholinyl, piperazinyl, (piperidyl)-piperidyl, or $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-5}


A 2
cont

alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and C₂₋₅ heterocyclic radical, but at least one of R₁₁ and R₁₂ is not H; or taken together, R₁₁ and R₁₂ with the N to which they are attached form a C₆₋₈ cycloalkylimino radical.

- 5
21. A pharmaceutical composition of claim 20, wherein said compound has a formula selected from 2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylamino)propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; and N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine.
- 10
- 15
- 20
- 25
- 30
- old San Fill*

22. A pharmaceutical composition of claim 20, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

23. A method for treating disorders mediated by the histamine H₃ receptor in a patient, said method comprising administering to the patient a pharmaceutically effective amount of compound of formula (I):



wherein both dashed lines are a carbon-carbon double bond, or both are absent;

R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl;

each of R₅, R₆, R₇ and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;

W is R₉, O-R₉, NR₁₀, -(CO)(O)R₉, -N(R₁₀)SO₂-R₉, -O(CO)R₉, -(CO)NR₁₀, or -N(R₁₀)-CO-R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆ alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R₁₀ is H, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclic radical;

Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆ alkoxy;

Z is C₂₋₆ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N,

NH, NG, S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅,
 SO₂R₁₅, SO₂N or CSR₁₅; or Z is NR₁₁R₁₂ where each of R₁₁ and R₁₂
 is independently selected from H, C₁₋₆ alkyl, phenyl, benzyl, C₃₋₈
 cycloalkyl, and C₂₋₅ heterocyclic radical; and R₁₅ is C₁₋₆ alkyl, C₂₋₆
 alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, or C₄₋₇ cycloalkenyl;
 provided that where R_c is WNR₁₁R₁₂, each of R₁₁ and R₁₂ being
 independently selected from C₁₋₈ alkyl, then at least one of the
 following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the
 dashed lines represent one carbon-carbon double bond or are
 absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is -R₉-, -
 NR₁₀-, -(CO)(O)R₉-, -O(CO)R₉-, -(CO)NHR₉-, or -N(R₁₀)(CO)R₉;
 and further provided that where each of R_a, R_b, R_d, and R_e is H,
 and W is a straight chain, unsubstituted alkoxy, then at least one
 of the following is true: Z is cyclic; the dashed lines represent
 one carbon-carbon double bond or are absent; or R₇ or R₈ is alkyl,
 alkoxy, halo, or amino; and
 each of the above hydrocarbonyl or heterocyclic groups being
 optionally substituted with between 1 and 3 substituents selected
 from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical, phenyl,
 and phenyl(C₁₋₃ alkyl); and wherein each of the above
 heterocyclic groups may be attached to the rest of the molecule
 by a carbon atom or a heteroatom;
 or a pharmaceutically acceptable salt, amide, ester, or hydrate
 thereof.

24. A method of claim 23, wherein said compound is selected
 from 2-[4-[3-(Piperidino)propylamino]phenyl]-7-
 methylimidazo[1,2-a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-
 enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methyl-
 imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine;
 [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-
 ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-
 methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-

5

A1
cont

10

15

20

pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylaminopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine; 2-(4-piperidino-propoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.


25. A method of claim 23, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

25

A1
cont

26. A method for treating a patient with a central nervous system disorder, said method comprising administering to the patient a pharmaceutically-effective amount of a compound of formula (I):

27. A compound of formula (I)(A):



wherein both dashed lines are a carbon-carbon double bond, or both are absent;

R_3 is H, C_{1-6} alkyl, phenyl, or benzyl;

each of R_5 , R_6 , R_7 and R_8 is independently H, C_{1-6} alkyl, C_{1-6} alkoxy, halo, or amino;

one of R_a , R_b , R_c , R_d , and R_e is -WYZ and the others are independently selected from H, C_{1-6} alkyl, C_{1-6} alkoxy, halo, and amino;

W is R_9 , $O-R_9$, NR_{10} , $-(CO)(O)R_9$, $-N(R_{10})SO_2-R_9$, $-O(CO)R_9$, $-(CO)NR_{10}$, or $-N(R_{10})-CO-R_9$, wherein R_9 is C_{1-6} alkylene, C_{2-6} alkynylene, C_{2-6} alkenylene, phenylene, or C_{2-5} heterocyclic bivalent radical, and R_{10} is H, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, phenyl, or C_{2-5} heterocyclic radical;

Y is absent, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, or C_{1-6} alkoxy;

Z is C_{2-8} heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2 , wherein G is R_{15} , COR_{15} , $COOR_{15}$, SO_2R_{15} , SO_2N or CSR_{15} ; or Z is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-6} alkyl, phenyl, benzyl, C_{3-8} cycloalkyl, and C_{2-5} heterocyclic radical; and R_{15} is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, C_{3-7} cycloalkyl, or C_{4-7} cycloalkenyl; provided that where R_c is $WNR_{11}R_{12}$, each of R_{11} and R_{12} being independently selected from C_{1-6} alkyl, then at least one of the

following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is $-R_9-$, $-NR_{10}-$, $-(CO)(O)R_9-$, $-O(CO)R_9-$, $-(CO)NHR_9-$, or $-N(R_{10})(CO)R_9-$; and further provided that where each of R_a , R_b , R_d , and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent one carbon-carbon double bond or are absent; or R_7 or R_8 is alkyl, alkoxy, halo, or amino; and each of the above hydrocarbonyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, C_{2-5} heterocyclic radical, phenyl, and phenyl(C_{1-3} alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

28. A method of claim 26, wherein said central nervous system disorder is selected from sleep/wake disorders, arousal/vigilance disorders, dementia, Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorder, learning and memory disorders, mild cognitive impairment, and schizophrenia.

29. A method of claim 26, wherein said central nervous system disorder is selected from Alzheimer's disease, epilepsy, eating disorders, learning and memory disorders, migraine, sleep/wake disorders, allergic rhinitis, schizophrenia, mild cognitive impairment, and asthma.

30. A method of claim 26, wherein said compound is selected from 2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-

A2
cont

A2
cat

5

10

15

20


25

a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylamino-propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine; 2-(4-piperidino-propoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

31. A method of claim 27, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.
32. A method of claim 26, wherein said disorder is selected from sleep/wake disorders, arousal/vigilance disorders, attention deficit hyperactivity disorder, and learning and memory disorders.

33. A method for treating a patient with an upper airway allergic response, said method comprising administering to the patient a pharmaceutically-effective amount of a compound of formula (I):

A2
cert



wherein both dashed lines are a carbon-carbon double bond, or both are absent;

R_3 is H, C_{1-6} alkyl, phenyl, or benzyl;

each of R_5 , R_6 , R_7 and R_8 is independently H, C_{1-6} alkyl, C_{1-6} alkoxy, halo, or amino;

one of R_a , R_b , R_c , R_d , and R_e is -WYZ and the others are independently selected from H, C_{1-6} alkyl, C_{1-6} alkoxy, halo, and amino;

W is R_9 , $O-R_9$, NR_{10} , $-(CO)(O)R_9$, $-N(R_{10})SO_2-R_9$, $-O(CO)R_9$, $-(CO)NR_{10}$, or $-N(R_{10})-CO-R_9$, wherein R_9 is C_{1-6} alkylene, C_{2-6} alkynylene, C_{2-6} alkenylene, phenylene, or C_{2-5} heterocyclic bivalent radical, and R_{10} is H, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, phenyl, or C_{2-5} heterocyclic radical;

Y is absent, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, or C_{1-6} alkoxy;

Z is C_{2-8} heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2 , wherein G is R_{15} , COR_{15} , $COOR_{15}$, SO_2R_{15} , SO_2N or CSR_{15} ; or Z is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-6} alkyl, phenyl, benzyl, C_{3-8}

5

A 4
cont

10

15

20

25

30

cycloalkyl, and C₂₋₅ heterocyclic radical; and R₁₅ is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, or C₄₋₇ cycloalkenyl; provided that where R_c is WNR₁₁R₁₂, each of R₁₁ and R₁₂ being independently selected from C₁₋₆ alkyl, then at least one of the following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is -R₉-, -NR₁₀-, -(CO)(O)R₉-, -O(CO)R₉-, -(CO)NHR₉-, or -N(R₁₀)(CO)R₉-; and further provided that where each of R_a, R_b, R_d, and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent one carbon-carbon double bond or are absent; or R₇ or R₈ is alkyl, alkoxy, halo, or amino; and each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical, phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

34. A method of claim 33, wherein said compound is selected from 2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-

5

A 1

Cont

10

15

20

Cycloheptylaminoxyphenyl)-7-methylimidazo[1,2-a]pyridine;
 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-
 a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-
 a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-
 a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-
 a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-
 methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-
 methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methyl-
 imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-
 Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-
 a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-
 phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; N,N-Diethyl-N'-
 [4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-
 diamine; 2-(4-piperidinopropoxyphenyl)-8-methylimidazo[1,2-
 a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-
 methylimidazo[1,2-a]pyridine.

35. A method of claim 33, wherein said compound is 2-(4-
 Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.